Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Excel Crop Care down 18% in Q1

Indian agrochemical company Excel Crop Care (Mumbai) recorded a 17.9% decline in net sales to Rs 1,739.4 million ($39.1 million at the current rate) in its first quarter ended June 30th 2011. An Indian Supreme Court ban in May on the production, sale and use of the insecticide/acaricide, endosulfan, a major product of the company normally accounting for over a third of sales, forced it to suspend production and sale of the active ingredient ( Agrow No 616, p 23). A provision of Rs 61 million ($1.4 million) for inventory items related to the ai led to net profit dropping by 64.4% to Rs 62.7 million ($1.4 million). Added to the provision made at the end of its fiscal year on March 31st, when net sales grew by 13% to Rs 7,022.7 million ($157.8 million), the aggregate provision amounts to Rs 163 million ($3.7 million). Insecticides made up some 57% of last fiscal year’s sales, while herbicides contributed just over a quarter. The Court has refused to lift the ban on endosulfan (see this issue).

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AG005091

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel